AMG 228

Drug Profile

AMG 228

Alternative Names: AMG228

Latest Information Update: 08 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a first-in-human phase I trial in Solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 12 Jan 2017 Amgen terminates a phase-I trial in Solid tumours (Late-stage disease) due to business decision in USA, Belgium, France, Germany and Australia (IV) (NCT02437916)
  • 14 Oct 2015 Phase-I clinical trials in Solid tumours (Late-stage disease) in Belgium, France and Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top